Biologics for the treatment of juvenile idiopathic arthritis: A systematic review and critical analysis of the evidence

Clinical Rheumatology

Volumn 27, Issue 1, 2008, Pages 67-76

  Gartlehner, Gerald ^a   Hansen, Richard A ^b   Jonas, Beth L ^c   Thieda, Patricia ^b   Lohr, Kathleen N ^d  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d IL   (United States)

Author keywords

Biologics; Juvenile idiopathic arthritis; Systematic review; Targeted immune modulators

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB;

ARTICLE; CLINICAL TRIAL; CLONUS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; HUMAN; HYPOTENSION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; NAUSEA; PANCYTOPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VASCULITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHROGRAPHY; BIOLOGICAL PRODUCTS; DATABASES AS TOPIC; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; JOINTS; QUALITY OF LIFE;

EID: 36549065772     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0654-6     Document Type: Article

References (50)

1. Manners PJ, Bower C (2002) Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol 29(7):1520-1530
2. Ravelli A, Martini A (2007) Juvenile idiopathic arthritis. Lancet 369(9563):767-778
3. Andersson Gare B (1999) Juvenile arthritis - who gets it, where and when? A review of current data on incidence and prevalence. Clin Exp Rheumatol 17(3):367-374
4. Newacheck PW, Taylor WR (1992) Childhood chronic illness: Prevalence, severity, and impact. Am J Public Health 82(3):364-371
5. Thompson SD, Moroldo MB, Guyer L et al (2004) A genome-wide scan for juvenile rheumatoid arthritis in affected sibpair families provides evidence of linkage. Arthritis Rheum 50(9):2920-2930
6. Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 31(2):390-392
7. Hashkes PJ, Laxer RM (2005) Medical treatment of juvenile idiopathic arthritis. JAMA 294(13):1671-1684
8. Minden K, Kiessling U, Listing J et al (2000) Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol 27(9):2256-2263
9. Wilkinson N, Jackson G, Gardner-Medwin J (2003) Biologic therapies for juvenile arthritis. Arch Dis Child 88(3):186-191
10. Gartlehner G, Hansen RA, Jonas BL et al (2006) The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: A systematic review and metaanalysis. J Rheumatol 33(12):2398-2408
11. Lovell DJ (2004) Preliminary data from a study of adalimumab in children with JIA. Arthritis Rheum 50:S436 (Suppl)
12. Irigoyen PI, Olson J, Hom C (2004) Treatment of systemic onset juvenile rheumatoid arthritis with anakinra. Arthritis Rheum 50:S437 (Suppl)
13. Reiff A (2005) The use of anakinra in juvenile arthritis. Curr Rheumatol Rep 7(6):434-440
14. Lovell DJ, Ruperto N, Cuttica R (2004) Randomized trial of infliximab plus methotrexate for the treatment of polyarticular juvenile rheumatoid arthritis poster. American College of Rheumatology 68th Annual Scientific Meeting. San Antonio, TX
15. Gartlehner G, Hansen RA, Thieda P et al (2005) Drug class review on targeted immune modulators. Drug Effectiveness Review Project, Portland
16. Fox DM (2005) Evidence of evidence-based health policy: The politics of systematic reviews in coverage decisions. Health Aff (Millwood) 24(1):114-122
17. Giannini EH, Ruperto N, Ravelli A et al (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40(7):1202-1209
18. Giannini EH, Lovell DJ, Felson DT et al (1994) Preliminary core set of outcome variables for use in JRA clinical trials. Arthritis Rheum 37:S428 (Suppl)
19. Harris RP, Helfand M, Woolf SH et al (2001) Current methods of the US Preventive Services Task Force: A review of the process. Am J Prev Med 20(3):21-35
20. Anonymous (2001) Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. CRD report number 4, 2nd edn. CRD, York
21. Deeks JJ, Dinnes J, D'Amico R et al (2003) Evaluating non-randomised intervention studies. Health Technol Assess 7(27):iIi-x, 1-173
22. ClinicalTrails.gov. (2007) BMS-188667 in children and adolescents with juvenile rheumatoid arthritis. http://wwwclinicaltrialsgov/ct/show/ NCT00095173?order=16. Cited 5 May 2007
23. Ruperto N (2006) 2006 EULAR meeting proceedings. 48-week data from the study of adalimumab in children with juvenile rheumatoid arthritis (JR). Ann Rheum Dis 65:OP0007 (Suppl)
24. Andrias R, Porras O, Rudge S (2002) Preliminary data from a study of kineret (anakinra) in children with juvenile rheumatoid arthritis abstract. Arthritis Rheum 46:496 (Suppl)
25. Ilowite NT, Reiff A, Rudge S et al (2006) Abstract 723: A randomized, multi-center, blinded, placebo-controlled study with an open-label run-in period to evaluate anakinra in polyarticular-course juvenile rheumatoid arthritis. American College of Rheumatology National Scientific Meeting
26. Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342(11):763-769
27. Horneff G, Schmeling H, Biedermann T et al (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63(12):1638-1644
28. Henrickson M, Reiff A (2004) Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 31(10):2055-2061
29. Kietz DA, Pepmueller PH, Moore TL (2002) Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 61(2):171-173
30. Quartier P, Taupin P, Bourdeaut F et al (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48(4):1093-1101
31. Russo RA, Katsicas MM, Zelazko M (2002) Etanercept in systemic juvenile idiopathic arthritis. Clin Exp Rheumatol 20(5):723-726
32. Lahdenne P, Vahasalo P, Honkanen V (2003) Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 62(3):245-247
33. CDER/FDA (1999) Food and drug administration center for biologics evaluation and research, statistical review and evaluation of BLA #98-1296. http://www.fda.gov/cder/biologics/review/etanimm052799r2.pdf
34. Lovell DJ, Giannini EH, Reiff A et al (2003) Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 48(1):218-226
35. Lovell DJ, Reiff A, Jones OY et al (2006) Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 54(6):1987-1994
36. Tauber T, Turetz J, Barash J et al (2006) Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS 10(1):26-29
37. Gerloni V, Pontikaki I, Gattinara M et al (2005) Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: Results of an open-label prospective study. Arthritis Rheum 52(2):548-553
38. Katsicas MM, Russo RA (2005) Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept. Clin Exp Rheumatol 23(4):545-548
39. Masatlioglu S, Gogus F, Cevrigen D (2002) Infliximab in the treatment of refractory juvenile idiopathic arthritis. Arthritis Rheum 46(9):S481
40. Scarazatti M, Beltramelli M, Dell'Era L (2001) Infliximab in juvenile idiopathis arthrits abstract. Ann Rheum Dis 60:iI17-ii53 (abstract P180)
41. Honkanen V, Tynjala P, Vahasalo P (2002) Infliximab in juvenile arthritis: 1-year follow up abstract. Arthritis Rheum 46:1272 (Suppl)
42. Woo P, Wilkinson N, Prieur AM et al (2005) Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: Proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 7(6):R1281-R1288
43. Yokota S, Miyamae T, Imagawa T et al (2005) Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52(3):818-825
44. Yokota S, Imagawa T, Mori M et al (2006) Abstract 722: Rapid improvement of signs and symptoms associated with systemic juvenile idiopathic arthritis (sJIA) by interleukin-6 (IL-6) blockade-results from a tocilizumab sJIA phase III clinical trial. American College of Rheumatology National Scientific Meetings
45. Genovese MC, Bathon JM, Martin RW et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 46(6):1443-1450
46. Higgins G, Jones K, Rennebohm R (2000) Variable response of systemic juvenile rheumatoid arthritis to etanercept abstract. Arthritis Rheum 43:S257 (Suppl)
47. Kimura Y, Pinho P, Walco G et al (2005) Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 32(5):935-942
48. Kietz DA, Pepmueller PH, Moore TL (2001) Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J Rheumatol 28(2):360-362
49. Haapasaari J, Kautiainen H, Hannula S et al (2002) Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis. Clin Exp Rheumatol 20(6):867-870
50. Schmeling H, Mathony K, John V et al (2001) A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: A pilot study. Ann Rheum Dis 60(4):410-412